Literature DB >> 10233987

Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

C M Browning1, L Cagnon, P D Good, J Rossi, D R Engelke, D M Markovitz.   

Abstract

Tat activation-response region (TAR) decoys have been developed for use in gene therapy for people infected with human immunodeficiency virus type 1 (HIV-1). When a TAR RNA decoy is overexpressed, it will bind Tat, thus leaving less of this crucial protein to bind to and activate the natural transcriptional promoter of HIV-1. Previous TAR decoy constructs have used HIV-1 TAR. However, recent epidemiological and biological data began to suggest that the TAR region from the human immunodeficiency virus type 2 (HIV-2) may suppress HIV-1 transcription and hence replication. We created a vector which overexpresses TAR-2 under the control of the human U6 small nuclear RNA gene promoter and here show that the U6-TAR-2 decoy construct potently inhibits both HIV-2 and HIV-1 gene expression. Further, this decoy construct is able to markedly suppress HIV-1 replication. Thus, we have directly proven that TAR-2 can suppress HIV-1 replication and suggest that the HIV-2 TAR decoy may prove useful for combating HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233987      PMCID: PMC112569     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Does HIV-2 infection provide cross-protection against HIV-1 infection?

Authors:  K Ariyoshi; M Schim van der Loeff; S Sabally; F Cham; T Corrah; H Whittle
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

2.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  Inhibition of HIV-1 replication by targeting the Rev protein.

Authors:  T Nakaya; S Iwai; K Fujinaga; E Otsuka; K Ikuta
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

4.  The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.

Authors:  T P Cujec; H Okamoto; K Fujinaga; J Meyer; H Chamberlin; D O Morgan; B M Peterlin
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

5.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.

Authors:  Y Zhu; T Pe'ery; J Peng; Y Ramanathan; N Marshall; T Marshall; B Amendt; M B Mathews; D H Price
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

6.  A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription.

Authors:  P R Bohjanen; R A Colvin; M Puttaraju; M D Been; M A Garcia-Blanco
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

7.  Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.

Authors:  C A Parada; R G Roeder
Journal:  Nature       Date:  1996-11-28       Impact factor: 49.962

8.  Expression of small, therapeutic RNAs in human cell nuclei.

Authors:  P D Good; A J Krikos; S X Li; E Bertrand; N S Lee; L Giver; A Ellington; J A Zaia; J J Rossi; D R Engelke
Journal:  Gene Ther       Date:  1997-01       Impact factor: 5.250

9.  RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication.

Authors:  M L Bonyhadi; K Moss; A Voytovich; J Auten; C Kalfoglou; I Plavec; S Forestell; L Su; E Böhnlein; H Kaneshima
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

10.  Inhibition of HIV-1 expression by HIV-2.

Authors:  J Rappaport; S K Arya; M W Richardson; G Baier-Bitterlich; P E Klotman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

View more
  7 in total

1.  A nucleolar TAR decoy inhibitor of HIV-1 replication.

Authors:  Alessandro Michienzi; Shirley Li; John A Zaia; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

2.  In vitro correlates of HIV-2-mediated HIV-1 protection.

Authors:  E G Kokkotou; J L Sankale; I Mani; A Gueye-Ndiaye; D Schwartz; M E Essex; S Mboup; P J Kanki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.

Authors:  Dana N Raugi; Geoffrey S Gottlieb; Papa S Sow; Macoumba Toure; Fatima Sall; Awa Gaye; Ibra N'doye; Nancy B Kiviat; Stephen E Hawes
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

4.  Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses.

Authors:  Kazushi Motomura; Jianbo Chen; Wei-Shau Hu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

5.  5'-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity.

Authors:  Sun-Young Hwang; Hwa-Young Sun; Kwang-Hoon Lee; Byung-Ha Oh; Yu Jin Cha; Byeang Hyean Kim; Joo-Yeon Yoo
Journal:  Nucleic Acids Res       Date:  2011-11-29       Impact factor: 16.971

Review 6.  Molecular strategies to inhibit HIV-1 replication.

Authors:  Morten Hjuler Nielsen; Finn Skou Pedersen; Jørgen Kjems
Journal:  Retrovirology       Date:  2005-02-16       Impact factor: 4.602

7.  Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology.

Authors:  Dimitrios Vlachakis; Georgia Tsiliki; Athanasia Pavlopoulou; Maria G Roubelakis; Spyridon Champeris Tsaniras; Sophia Kossida
Journal:  Evol Bioinform Online       Date:  2013-05-16       Impact factor: 1.625

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.